Get the Stockscreener App
3.85
3.75%
-0.15
After Hours:
3.87
0.02
+0.52%
Quantum Biopharma Ltd stock is traded at $3.85, with a volume of 192.70K.
It is down -3.75% in the last 24 hours and up +17.38% over the past month.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
See More
Previous Close:
$4.00
Open:
$4
24h Volume:
192.70K
Relative Volume:
0.99
Market Cap:
$31.14M
Revenue:
-
Net Income/Loss:
$-31.97M
P/E Ratio:
-0.466
EPS:
-8.2612
Net Cash Flow:
$-5.66M
1W Performance:
+5.19%
1M Performance:
+17.38%
6M Performance:
-11.49%
1Y Performance:
-54.89%
1-Day Range:
$3.80
$4.00
1-Week Range:
$3.52
$4.34
52-Week Range:
$2.07
$14.85
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
3.85 | 31.14M | 0 | -31.97M | -5.66M | -8.2612 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quantum Biopharma Ltd Stock (QNTM) Latest News
Quantum BioPharma Advances Lucid-MS Toward Phase 2 Trial Following FDA IND Clearance - Pulse 2.0
Quantum BioPharma (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing - Benzinga
Quantum BioPharma Licensee Unbuzzd Wellness Names "Zappy" Zapolin CEO Ahead of Planned Stock Exchange Lis - Benzinga
Quantum BioPharma (QNTM) gets 7% of Unbuzzd sales until a payment threshold changes the rate. - Stock Titan
Quantum BioPharma Ltd. (QNTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
A drink mix lowered blood alcohol levels over 40% faster than a comparison group for most participants, on average. - Stock Titan
Quantum BioPharma (QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments - Yahoo Finance
Quantum BioPharma (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments - Benzinga
Quantum Biopharma Q4 2025 Earnings: Per-Share Loss of 0.71 Reported as Revenue Detail Remains Unavailable - siam.in
Cash runway to 2028 comes with fresh dilution at Quantum BioPharma (QNTM) - stocktitan.net
Quantum BioPharma (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 P - Benzinga
Quantum BioPharma (NASDAQ: QNTM) Picks Up Buy Rating and $8 Price Target as Phase 2 MS Trial Nears - Benzinga
Buy rating puts spotlight on Quantum BioPharma (QNTM) - Stock Titan
Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target - GlobeNewswire
Quantum BioPharma (QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit - Yahoo Finance
FDA clears Quantum Biopharma (QNTM) to test new MS drug in Phase 2 trials - Stock Titan
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto - Stock Titan
Stray alert on Quantum BioPharma withdrawn - marketscreener.com
NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS Research - GlobeNewswire
Nearly 2.9 million people have MS. A drug candidate targeting nerve coating gets FDA trial clearance. - Stock Titan
Quantum BioPharma (QNTM.CN) Receives FDA Clearance for Historic Phase 2 Trial of Lucid-MS in Multiple Sclerosis - kalkine.ca
Quantum BioPharma Ltd.: Financial Data Forecasts Estimates and Expectations | QNTM | CA74764Y2050 - marketscreener.com
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance - The Chronicle-Journal
Quantum BioPharma receives FDA clearance for MS phase 2 trial By Investing.com - Investing.com Australia
Quantum BioPharma receives FDA clearance for MS phase 2 trial - Investing.com
Quantum BioPharma Ltd. Receives FDA Clearance To Begin Phase 2 Trial Of Lucid-MS For Multiple Sclerosis - marketscreener.com
Quantum Biopharma amends Form 6-K to add exhibit to F-3 registration statement - Bitget
Quantum Biopharma (QNTM) folds April 2 press release into shelf filing - Stock Titan
April press release now tied to Quantum Biopharma (QNTM) securities registration - Stock Titan
March 30 release now part of Quantum Biopharma (QNTM) registration - Stock Titan
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach - Almaguin News
Why Did Quantum BioPharma (CN:TCM) Stock Surge 6.846% on 4 September 2026? - kalkine.ca
Quantum BioPharma engages FinnCom for investor awareness - scanx.trade
FDA Clears Quantum BioPharma’s Lucid-MS Phase 2 Trial — Could QNTM Be Entering a Pivotal Clinical Chapter? - kalkine.ca
QNTM Should I Buy - Intellectia AI
Quantum BioPharma settles CAD$123,487 debt via Class B shares - scanx.trade
Quantum BioPharma Ltd. (NASDAQ: QNTM) Share Price, QNTM Stock News, QNTM Share Price & Updates - kalkine.ca
Quantum BioPharma Stock Slides 5.75%: Is Clinical Execution Risk Weighing on QNTM Sentiment? - kalkine.ca
Quantum BioPharma Stock Slides 5.75% as CN:QNTM Delisting Plans Add Fresh Pressure to QNTM Sentiment - kalkine.ca
Giving up one stock exchange but not Nasdaq, Quantum BioPharma (NASDAQ: QNTM) reshapes where its shares trade - Stock Titan
Quantum BioPharma to Delist Class B Shares from Canadian Securities Exchange - marketscreener.com
Quantum BioPharma Ltd. Applies for Voluntary Delisting of Class B Shares from Canadian Securities Exchange - Quiver Quantitative
Quantum BioPharma to Voluntarily Delist Class B Shares from CSE, Consolidating Trading on Nasdaq - kalkine.ca
Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange - Yahoo Finance
Quantum BioPharma Ltd Key Financial Ratios – Valuation, Profitability & More - Value Research
QNTM Initiated Coverage by Rodman & Renshaw -- Price Target Set at $8.00 - GuruFocus
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential - TradingView
Quantum BioPharma stock initiated with buy rating at Rodman & Renshaw - Investing.com Nigeria
Quantum BioPharma Ltd Peer Comparison – Compare with Others - Value Research
Quantum BioPharma Ltd. (CN:QNTM) Rises 3.07% as FDA-Cleared Lucid-MS Program Strengthens Investor Optimism - kalkine.ca
QNTM Stock Analysis: Price-to-Sales Signals Market Skepticism De - GuruFocus
Quantum Biopharma Ltd Stock (QNTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):